Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|September 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-09-01-2012
  • Volume 21
  • Issue 9

Selection of Phase I Service Providers

Author(s)ISR Reports

Tufts CSDD

What are the most important factors in selecting a Phase I service provider?

That depends how we look at the data from ISR's latest report, "2012 CRO Quality Benchmarking—Phase I Service Providers." Of the 61 executives responsible for Phase I study conduct and outsourcing, more selected "prior positive experience with a service provider" than any other attribute as the single most important driver of selection. However, when asked to indicate their top five drivers of selection, more respondents chose "access to patient populations" among their top five than any other attribute.

Attributes that fuel service provider selection.

This is notable considering the other 20 attributes respondents had to choose from are historically critical skills such as therapeutic expertise, project management, timelines management, and even the experience of the Phase I unit's lead investigator.

For now, historical relationships will continue to get a Phase I provider invited to bid.

Going forward, the ability to demonstrate patient—not just healthy volunteer—recruitment capabilities will make the difference between a win and a loss.

—Industry Standard Research, www.ISRreports.com.

Articles in this issue

about 14 years ago

We Still Love Paper

about 14 years ago

Flow Cytometry

about 14 years ago

ePRO in Diabetes Studies

about 14 years ago

A New Paradigm

about 14 years ago

Act cover

about 14 years ago

Regulators Must Modify Approach

about 14 years ago

Cover

Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.